Skip to content
Screener

Total Equity at other companies

Pfizer logo
PfizerPFE
$90.1B-0.3%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$84.97B+8.3%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$31.71B+5.9%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$402.63M-10.0%
Arvinas logo
ArvinasARVN
$386.8M-41.4%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
$487.28M+81.8%

Other financials

Income statement

See full
Revenue$65.0M+466%
Operating income-$75.6M+10.6%
Net income-$61.2M+20.1%
EPS (diluted)-$0.62+34.7%

Balance sheet

See full
Cash & equivalents$124.5M-62.9%
Total debt$80.1M-8.5%
Total assets$1.6B+45.5%

Cash flow

See full
Operating cash flow-$54.1M+9.7%
CapEx$473.0K-31.9%
Free cash flow-$54.5M+10.0%

Valuation

See full
Market cap$8.68B+199%
Enterprise value$8.63B+225%
P/S82.6×+17.8×

Profitability

See full
Operating margin-333.5%-114pp
Net margin-285.3%-99.7pp
FCF margin-226.6%-84.9pp

Returns & leverage

See full
Return on equity-24.2%-5.2pp
Debt / equity0.1×0.0×
Current ratio10.3×+2.0×

Where this comes from

Reported directly by Kymera Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 7:15 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-333849
Line itemJune 30,2026December 31,2025
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 0 shares issued and outstanding as of June 30, 2026 and December 31, 2025
Common stock, $0.0001 par value; 150,000,000 shares authorized at June 30, 2026 and December 31, 2025, 82,788,253 and 81,323,532 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively88
Additional paid-in capital2,712,8112,643,817
Accumulated deficit(1,196,406)(1,065,961)
Accumulated other comprehensive (loss) income(7,157)1,800
Total stockholders’ equity1,509,2561,579,664
Total liabilities and stockholders’ equity$1,645,444$1,742,812

Item 1. Financial Statements.

FAQ

What is Kymera Therapeutics's total equity?
Kymera Therapeutics (KYMR) reported total equity of $1.51B in Q2 2026.
How has Kymera Therapeutics's total equity changed year-over-year?
Kymera Therapeutics's total equity increased by 55.4% year-over-year, from $971.48M to $1.51B.
What is the long-term trend for Kymera Therapeutics's total equity?
Over 5 years (2020 to 2025), Kymera Therapeutics's total equity has grown at a 41.0% compound annual growth rate (CAGR), from $283.89M to $1.58B.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Ask your AI about Kymera Therapeutics's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude